Verition Fund Management
SRPT icon

Verition Fund Management’s Sarepta Therapeutics SRPT Stock Holding History

Verition Fund Management’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-148,367
Closed -$2.86M – 3921
2025
Q3 		$2.86M Buy
148,367
+58,479
+65% +$1.04M 0.01% 1678
2025
Q2 		$1.54M Buy
89,888
+16,148
+22% +$689K 0.01% 2149
2025
Q1 		$4.71M Buy
73,740
+68,424
+1,287% +$7.2M 0.02% 882
2024
Q4 		$646K Buy
5,316
+1,830
+52% +$224K ﹤0.01% 2325
2024
Q3 		$435K Sell
3,486
-8,475
-71% -$1.17M ﹤0.01% 2406
2024
Q2 		$1.89M Buy
11,961
+6,531
+120% +$839K 0.01% 1303
2024
Q1 		$703K Buy
5,430
+1,896
+54% +$232K ﹤0.01% 1818
2023
Q4 		$341K Buy
3,534
+698
+25% +$67K ﹤0.01% 1731
2023
Q3 		$344K Sell
2,836
-36,200
-93% -$4.09M ﹤0.01% 1647
2023
Q2 		$4.47M Buy
39,036
+32,976
+544% +$4.25M 0.06% 398
2023
Q1 		$835K Sell
6,060
-1,543
-20% -$200K 0.01% 1022
2022
Q4 		$985K Buy
7,603
+3,346
+79% +$388K 0.02% 920
2022
Q3 		$471K Buy
+4,257
New +$429K 0.01% 1937
2021
Q3 		– Sell
-4,565
Closed -$355K – 2280
2021
Q2 		$355K Sell
4,565
-7
-0.2% -$531 ﹤0.01% 1262
2021
Q1 		$341K Buy
+4,572
New +$422K ﹤0.01% 1049
2020
Q4 		– Sell
-3,476
Closed -$515K – 1372
2020
Q3 		$488K Buy
+3,476
New +$528K 0.01% 591
2020
Q1 		– Sell
-5,779
Closed -$746K – 1028
2019
Q4 		$746K Buy
+5,779
New +$583K 0.01% 535
2019
Q2 		– Sell
-7,482
Closed -$892K – 1349
2019
Q1 		$892K Buy
+7,482
New +$962K 0.03% 439
2018
Q4 		– Sell
-6,646
Closed -$1.07M – 1224
2018
Q3 		$1.07M Buy
6,646
+3,506
+112% +$479K 0.04% 538
2018
Q2 		$415K Buy
+3,140
New +$296K 0.03% 757

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Verition Fund Management's SRPT Position: Q4 2025 in Review

Verition Fund Management sold out of Sarepta Therapeutics (SRPT) in Q4 2025, closing a stake of 148,367 shares — an estimated $2.86M sold.

Verition Fund Management first reported a position in SRPT in Q2 2018 and held it in 20 quarters. The position peaked at $4.71M in Q1 2025. 347 funds tracked by Wall St. Rank hold SRPT as of Q4 2025.

  • Verition Fund Management reported no remaining Sarepta Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Verition Fund Management sold 148,367 Sarepta Therapeutics shares in Q4 2025, an estimated $2.86M.
  • Verition Fund Management first reported a position in Sarepta Therapeutics in Q2 2018 and held it in 20 quarters.
  • Verition Fund Management's Sarepta Therapeutics position peaked at $4.71M in Q1 2025.
  • 347 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q4 2025.

Based on Verition Fund Management's 13F filing for Q4 2025, filed 13 Feb 2026.